Published in Women's Health Weekly, July 6th, 2006
Lilly's study is among the first bodies of research evaluating the potential use of biomarkers with chemotherapy agents. Results were announced at the 42nd American Society of Clinical Oncology (ASCO) annual meeting in Atlanta, Georgia.
The phase 2 study was a randomized, double-blind trial of 92 patients with locally advanced or metastatic breast cancer (MBC). The...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly